Agency Information Collection Activities; Proposed Collection; Comment Request; Medical Device Labeling Regulations, 21959-21962 [E8-8710]

Download as PDF 21959 Federal Register / Vol. 73, No. 79 / Wednesday, April 23, 2008 / Notices OMB No.: 0970–0198. Description: The Child Care and Development Fund (CCDF) Tribal Plan serves as the agreement between the applicant (Indian Tribes, tribal consortia and tribal organizations) and the Federal government that describes how tribal applicants will operate CCDF Block Grant programs. The Tribal Plan provides assurances that the CCDF funds will be administered in conformance with legislative requirements, federal regulations at 45 CFR parts 98 and 99 and other applicable instructions or guidelines issued by the Administration for Children and Families (ACF). Tribes must submit a new CCDF Tribal Plan every two years in accordance with 45 CFR 98.17. Respondents: Tribal CCDF programs (259 total). ANNUAL BURDEN ESTIMATES Number of respondents Instrument CCDF Tribal Plan ............................................................................................ CCDF Tribal Plan Amendments ...................................................................... Estimated Total Annual Burden Hours: 4,921. Additional Information: Copies of the proposed collection may be obtained by writing to the Administration for Children and Families, Office of Administration, Office of Information Services, 370 L’Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer. All requests should be identified by the title of the information collection. E-mail address: infocollection@acf.hhs.gov. OMB Comment: OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the Federal Register. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, Fax: 202–395–6974, Attn: Desk Officer for the Administration for Children and Families. Dated: April 16, 2008. Janean Chambers, Reports Clearance, Officer. [FR Doc. E8–8648 Filed 4–22–08; 8:45 am] BILLING CODE 4184–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration mstockstill on PROD1PC66 with NOTICES [Docket No. FDA–2008–N–0227] Agency Information Collection Activities; Proposed Collection; Comment Request; Medical Device Labeling Regulations AGENCY: Food and Drug Administration, HHS. VerDate Aug<31>2005 16:58 Apr 22, 2008 Jkt 214001 ACTION: 259 259 Notice. SUMMARY: The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on medical device labeling regulations. DATES: Submit written or electronic comments on the collection of information by June 23, 2008. ADDRESSES: Submit electronic comments on the collection of information to http:// www.regulations.gov. Submit written comments on the collection of information to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: Denver Presley, Jr., Office of the Chief Information Officer (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827– 1772. SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501–3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. ‘‘Collection of information’’ is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. PO 00000 Frm 00060 Fmt 4703 Sfmt 4703 Number of responses per respondent 1 1 Average burden hours per response 17.5 1.5 Total burden hours 4,532.5 388.5 Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information set forth in this document. With respect to the following collection of information, FDA invites comments on these topics: (1) Whether the proposed collection of information is necessary for the proper performance of FDA’s functions, including whether the information will have practical utility; (2) the accuracy of FDA’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology. Medical Device Labeling Regulations— 21 CFR Parts 800, 801, and 809 (OMB Control Number 0910–0485)—Extension Section 502 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 352), among other things, establishes requirements for the label or labeling of a medical device so that it is not misbranded and subject to a regulatory action. Certain provisions under section 502 of the act require manufacturers, importers, and distributors of medical devices to disclose information about themselves or the devices, on the labels or labeling for the devices. Section 502(b) of the act requires that for packaged devices, the label must bear E:\FR\FM\23APN1.SGM 23APN1 mstockstill on PROD1PC66 with NOTICES 21960 Federal Register / Vol. 73, No. 79 / Wednesday, April 23, 2008 / Notices the name and place of business of the manufacturer, packer, or distributor as well as an accurate statement of the quantity of the contents. Section 502(f) of the act requires that the labeling for a device must contain adequate directions for use. FDA may however, grant an exemption, if the agency determines that the adequate directions for use labeling requirements are not necessary for the particular case, as it relates to protection of the public health. FDA regulations under parts 800, 801, and 809 (21 CFR parts 800, 801, and 809) require disclosure of specific information by manufacturers, importers, and distributors of medical devices about themselves or the devices, on the label or labeling for the devices to health professionals and consumers. FDA issued these regulations under the authority of sections 201, 301, 502, and 701 of the act (21 U.S.C. 321, 331, 352, and 371). Most of the regulations under parts 800, 801, and 809 are derived from requirements of section 502 of the act, which provides in part, that a device shall be misbranded if among other things, its label or labeling fails to bear certain required information concerning the device, is false or misleading in any particular way, or fails to contain adequate directions for use. Reporting Burden Sections 800.10(a)(3) and 800.12(c) require that the label for contact lens cleaning solutions bear a prominent statement alerting consumers of the tamper-resistant feature. Further, § 800.12 requires that packaged contact lens cleaning solutions contain a tamper-resistant feature, to prevent malicious adulteration. Section 800.10(b)(2) requires that the labeling for liquid ophthalmic preparations packed in multiple-dose containers provide information on the duration of use and the necessary warning information to afford adequate protection from contamination during use. Section 801.1 requires that the label for a device in package form, contain the name and place of business of the manufacturer, packer, or distributor. Section 801.5 requires that labeling for a device include information on intended use as defined under § 801.4 and provide adequate directions to assure safe use by the lay consumers. Section 801.61 requires that the principal display panel of an over-thecounter (OTC) device in package form must bear a statement of the identity of the device. The statement of identity of the device must include the common name of the device followed by an VerDate Aug<31>2005 16:58 Apr 22, 2008 Jkt 214001 accurate statement of the principal intended actions of the device. Section 801.62 requires that the label for an OTC device in package form must bear a statement of declaration of the net quantity of contents. The label must express the net quantity in terms of weight, measure, numerical count, or a combination of numerical count and weight, measure, or size. Section 801.109 establishes labeling requirements for prescription devices, in which the label for the device must describe the application or use of the device, and contain a cautionary statement restricting the device for sale by, or on the order of an appropriate professional. For prescription by a licensed practitioner, § 801.110 establishes labeling requirements for a prescription device delivered to the ultimate purchaser or user. The device must be accompanied by labeling bearing the name and address of the licensed practitioner, directions for use, and cautionary statements if any, provided by the order. Section 801.150(e) requires a written agreement between firms involved when a non-sterile device is assembled or packaged with labeling that identifies the final finished device as sterile, for which the device is ultimately introduced into interstate commerce to an establishment or contract manufacturer to be sterilized. When a written agreement complies with the requirements under § 801.150(e), FDA takes no regulatory action against the device as being misbranded or adulterated. In addition, § 801.150(e) requires that each pallet, carton, or other designated unit, be conspicuously marked to show its non-sterile nature when introduced into interstate commerce, and while being held prior to sterilization. Section 801.405(b)(1) provides for labeling requirements for articles, including repair kits, re-liners, pads, and cushions, intended for use in temporary repairs and refitting of dentures for lay persons. Section 801.405(b)(1) also requires that the labeling contain the word ‘‘emergency’’ preceding and modifying each indication-for-use statement for denture repair kits and the word ‘‘temporary’’ preceding and modifying each indication-for-use statement for reliners, pads, and cushions. Section 801.405(c) provides for labeling requirements that contain essentially the same information described under § 801.405(b)(1). The information is intended to enable a lay person to understand the limitations of PO 00000 Frm 00061 Fmt 4703 Sfmt 4703 using OTC denture repair kits, and denture re-liners, pads, and cushions. Section 801.420(c)(1) requires that manufacturers or distributors of hearing aids develop a user instructional brochure to be provided by the dispenser of the hearing aid to prospective users. The brochure must contain detailed information on the use and maintenance of the hearing aid. Section 801.420(c)(4) establishes requirements that the user instructional brochure or separate labeling, provide for technical data elements useful for selecting, fitting, and checking the performance of a hearing aid. In addition, § 801.420(c)(4) provides for testing requirements to determine that the required data elements must be conducted in accordance with the American National Standards Institute’s (ANSI) ‘‘Specification of Hearing Aid Characteristics,’’ ANSI S3.22–1996 (ASA 70–1996); (Revision of ANSI S3.22–1987), which is incorporated by reference in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. Section 801.421(b) establishes requirement for the hearing aid dispenser to provide prospective users with a copy of the user instructional brochure along with an opportunity to review comments, either orally or by the predominant method of communication used during the sale. Section 801.421(c) establishes requirements for the hearing aid dispenser to provide a copy of the user instructional brochure to the prospective purchaser of any hearing aid upon request or, if the brochure is unavailable, provide the name and address of the manufacturer or distributor from which it may be obtained. Section 801.430(d) establishes labeling requirements for menstrual tampons to provide information on signs, risk factors, and ways to reduce the risk of Toxic Shock Syndrome (TSS). Section 801.430(e)(2) requires menstrual tampon package labels to provide information on the absorbency term based on testing required under § 801.430(f) and an explanation of selecting absorbencies that reduce the risk of contracting TSS. Section 801.430(f) establishes requirements that manufacturers of menstrual tampons devise and follow an ongoing sampling plan for measuring the absorbency of menstrual tampons. Further, manufacturers must use the method and testing parameters described under this section. Section 801.435(b), (c), and (h) establishes requirements for condom labeling to bear an expiration date that E:\FR\FM\23APN1.SGM 23APN1 21961 Federal Register / Vol. 73, No. 79 / Wednesday, April 23, 2008 / Notices is supported by testing that demonstrates the integrity of three random lots of the product. Section 809.10(a) and (b) establishes requirements that a label for an in vitro diagnostic device and the accompanying labeling (package insert), must contain information identifying its intended use, instructions for use and lot or control number, and source. Section 809.10(d)(1) provides that the labeling requirements for general purpose laboratory reagents may be exempt from the requirements of § 809.10(a) and (b), if the labeling contains information identifying its intended use, instructions for use, lot or control number, and source. Section 809.10(e) provides that the labeling for ‘‘Analytic Specific Reagents’’ (ASRs) must provide information identifying the quantity or proportion or each reagent ingredient, instructions for use, lot or control number, and source. Section 809.10(f) provides that, the labeling for OTC test sample collection systems for drugs of abuse must include information on the intended use, specimen collection instructions, identification system, and information about use of the test results. In addition, § 809.10(f) requires that this information be in a language appropriate for the intended users. Section 809.30(d) requires that advertising and promotional materials for ASRs include the identity and purity of the ASR and the identity of the analyte. Recordkeeping Burden Section 801.150(a)(2) establishes recordkeeping requirements for reprocessors, re-labelers, or re-packagers to retain a copy of the agreement containing the specifications for the processing, labeling, or repacking of the device for 2 years after the shipment or delivery of the device. Section 801.150(a)(2) also requires that the subject respondents make copies of this agreement available for inspection at any reasonable hour to any officer or employee of the Department of Health and Human Services (DHHS), upon their request. Section 801.421(d) establishes requirements for hearing aid dispensers to retain copies of all physician statements or any waivers of medical evaluation for 3 years after dispensing the hearing aid. Section 801.410(e) requires copies of invoices, shipping documents, and records of sale or distribution of all impact resistant lenses, including finished eyeglasses and sunglasses, be maintained for 3 years by the retailer and made available upon request by any officer or employee of FDA or by any other officer or employee acting on behalf of the Secretary of Health and Human Services. Section 801.410(f) requires that the results of impact tests and description of the test method and apparatus be retained for a period of 3 years. Section 801.421(d) requires hearing aid dispensers to retain a copy of any written statement from a physician required under § 801.421(a)(1), or any written statement waiving medical evaluation required under § 801.421(a)(2)(iii) for 3 years after the dispensing the hearing aid. Section 801.435(g) requires latex condom manufacturers to document and provide, upon request, an appropriate justification for the application of the testing data from one product on any variation of that product to support expiration dating in the user labeling. FDA estimates the burden of this collection of information as follows: TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1 Annual Frequency per Response No. of Respondents 21 CFR Section Total Annual Responses Hours per Response Total Hours 800.10(a)(3) and 800.12(c) 4 10 40 1 40 800.10(b)(2) 4 10 40 40 1,600 801.1 30,000 3.5 105,000 0.1 10,500 801.5 5,000 3.5 17,500 22.35 391,125 801.61 5,000 3.5 17,500 1 17,500 801.62 1,000 5 5,000 1 5,000 801.109 18,000 3.5 63,000 17.77 1,119,510 801.110 10,000 50 500,000 0.25 125,000 2 1 2 0.50 1 801.405(b)(1) 40 1 40 4 160 801.405(c) 40 1 40 4 160 801.420(c)(1) 275 5 1,375 40 55,000 801.420(c)(4) 275 5 1,375 80 110,000 801.421(b) 10,000 160 1,600,000 0.30 480,000 801.421(c) 10,000 5 50,000 0.17 8,500 801.430(d) 8 5 40 2 80 801.430(e)(2) 8 5 40 2 80 mstockstill on PROD1PC66 with NOTICES 801.150(e) VerDate Aug<31>2005 16:58 Apr 22, 2008 Jkt 214001 PO 00000 Frm 00062 Fmt 4703 Sfmt 4703 E:\FR\FM\23APN1.SGM 23APN1 21962 Federal Register / Vol. 73, No. 79 / Wednesday, April 23, 2008 / Notices TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1—Continued Annual Frequency per Response No. of Respondents 21 CFR Section 801.430(f) Total Annual Responses Hours per Response Total Hours 8 5 40 80 3,200 135 1 135 96 12,960 1,700 6 10,200 80 816,000 809.10(d)(1) 300 2 600 40 24,000 809.10(e) 300 25 7,500 1 7,500 809.10(f) 20 1 20 100 2,000 809.30(d) 300 25 7,500 1 7,500 801.435(b), (c), and (h) 809.10(a) and (b) Total 1 There 3,197,416 are no capital costs or operating and maintenance costs associated with this collection of information. TABLE 2.—ESTIMATED ANNUAL RECORDKEEPING BURDEN1 No. of Recordkeepers 21 CFR Section Annual Frequency per Recordkeeping Total Annual Records Hours per Record Total Hours 801.150(a)(2) 57 1 57 0.50 28 801.410(e) 30 769,000 23,070,000 0.25 5,767,500 801.410(f) 30 769,000 23,070,000 0.25 5,767,500 801.421(d) 10,000 160 1,600,000 0.25 400,000 Total Hours mstockstill on PROD1PC66 with NOTICES 1 There 11,935,028 are no capital costs or operating and maintenance costs associated with this collection of information. This regulation also refers to previously approved collections of information found in FDA regulations. The collections of information under §§ 800.12(d) and 801.437(i) have been approved under OMB control number 0910–0183; the collections of information under § 800.12(e) have been approved under OMB control number 0910–0231; and the collections of information under § 801.435(g) have been approved under OMB control number 0910–0073. Further, FDA concludes that labeling statements under §§ 801.63, 801.405(b)(2) and (b)(3), 801.420(c)(2) and (c)(3), 801.430(c) and (e)(1), 801.433, 801.437(d) through (g), 809.30(d)(2) and (d)(3), and 809.30(e) do not constitute a ‘‘collection of information’’ under the PRA. Rather, these labeling statements are ‘‘public disclosure’’ of information originally supplied by the Federal Government to the recipient for the purpose of ‘‘disclosure to the public’’ (5 CFR 1320.3(c)(2)). Reporting These estimates are based on FDA’s registration and listing database for medical device establishments, agency VerDate Aug<31>2005 16:58 Apr 22, 2008 Jkt 214001 communications with industry, and FDA’s knowledge of and experience with device labeling. Recordkeeping These estimates are based on FDA’s registration and listing database for medical device establishments, agency communications with industry, and FDA’s knowledge of and experience with device labeling. In addition, the Vision Council of America provided the growth rate used to estimate the burden under § 801.410(e) through (f). This regulation also refers to previously approved collections of information found in FDA regulations. The collections of information under §§ 800.12(d) and 801.437(i) have been approved under OMB control number 0910–0183; and the collections of information under § 800.12(e) have been approved under OMB control number 0910–0231. The information collection requirements under §§ 801.22, 801.63, 801.405(b)(2) and (b)(3), 801.420(c)(2) and (c)(3), 801.430(c) and (e)(1), 801.433, 801.437(d) through (g), 809.30(d)(2) and (d)(3), and 809.30(e) are not considered information collection because the public PO 00000 Frm 00063 Fmt 4703 Sfmt 4703 information is originally supplied by the Federal Government to the recipient for the purpose of disclosure to the public (5 CFR 1320.3(c)(2)). We have not estimated a burden for information that is disclosed to third parties, because it is a ‘‘usual and customary’’ part of a medical device manufacturer, distributor, or importer’s normal business activities. Nor have we estimated a burden for time that is spent designing labels to improve the format or presentation. Please note that on January 15, 2008, the FDA Division of Dockets Management Web site transitioned to the Federal Dockets Management System (FDMS). FDMS is a Government-wide, electronic docket management system. Electronic comments or submissions will be accepted by FDA only through FDMS at http://www.regulations.gov. Dated: April 16, 2008. Jeffrey Shuren, Associate Commissioner for Policy and Planning. [FR Doc. E8–8710 Filed 4–22–08; 8:45 am] BILLING CODE 4160–01–S E:\FR\FM\23APN1.SGM 23APN1

Agencies

[Federal Register Volume 73, Number 79 (Wednesday, April 23, 2008)]
[Notices]
[Pages 21959-21962]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-8710]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2008-N-0227]


Agency Information Collection Activities; Proposed Collection; 
Comment Request; Medical Device Labeling Regulations

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing an 
opportunity for public comment on the proposed collection of certain 
information by the agency. Under the Paperwork Reduction Act of 1995 
(the PRA), Federal agencies are required to publish notice in the 
Federal Register concerning each proposed collection of information, 
including each proposed extension of an existing collection of 
information, and to allow 60 days for public comment in response to the 
notice. This notice solicits comments on medical device labeling 
regulations.

DATES: Submit written or electronic comments on the collection of 
information by June 23, 2008.

ADDRESSES: Submit electronic comments on the collection of information 
to http://www.regulations.gov. Submit written comments on the 
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, 
Rockville, MD 20852. All comments should be identified with the docket 
number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Denver Presley, Jr., Office of the 
Chief Information Officer (HFA-250), Food and Drug Administration, 5600 
Fishers Lane, Rockville, MD 20857, 301-827-1772.

SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal 
agencies must obtain approval from the Office of Management and Budget 
(OMB) for each collection of information they conduct or sponsor. 
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 
1320.3(c) and includes agency requests or requirements that members of 
the public submit reports, keep records, or provide information to a 
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) 
requires Federal agencies to provide a 60-day notice in the Federal 
Register concerning each proposed collection of information, including 
each proposed extension of an existing collection of information, 
before submitting the collection to OMB for approval. To comply with 
this requirement, FDA is publishing notice of the proposed collection 
of information set forth in this document.
    With respect to the following collection of information, FDA 
invites comments on these topics: (1) Whether the proposed collection 
of information is necessary for the proper performance of FDA's 
functions, including whether the information will have practical 
utility; (2) the accuracy of FDA's estimate of the burden of the 
proposed collection of information, including the validity of the 
methodology and assumptions used; (3) ways to enhance the quality, 
utility, and clarity of the information to be collected; and (4) ways 
to minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques, when 
appropriate, and other forms of information technology.

Medical Device Labeling Regulations--21 CFR Parts 800, 801, and 809 
(OMB Control Number 0910-0485)--Extension

    Section 502 of the Federal Food, Drug, and Cosmetic Act (the act) 
(21 U.S.C. 352), among other things, establishes requirements for the 
label or labeling of a medical device so that it is not misbranded and 
subject to a regulatory action. Certain provisions under section 502 of 
the act require manufacturers, importers, and distributors of medical 
devices to disclose information about themselves or the devices, on the 
labels or labeling for the devices. Section 502(b) of the act requires 
that for packaged devices, the label must bear

[[Page 21960]]

the name and place of business of the manufacturer, packer, or 
distributor as well as an accurate statement of the quantity of the 
contents. Section 502(f) of the act requires that the labeling for a 
device must contain adequate directions for use. FDA may however, grant 
an exemption, if the agency determines that the adequate directions for 
use labeling requirements are not necessary for the particular case, as 
it relates to protection of the public health.
    FDA regulations under parts 800, 801, and 809 (21 CFR parts 800, 
801, and 809) require disclosure of specific information by 
manufacturers, importers, and distributors of medical devices about 
themselves or the devices, on the label or labeling for the devices to 
health professionals and consumers. FDA issued these regulations under 
the authority of sections 201, 301, 502, and 701 of the act (21 U.S.C. 
321, 331, 352, and 371). Most of the regulations under parts 800, 801, 
and 809 are derived from requirements of section 502 of the act, which 
provides in part, that a device shall be misbranded if among other 
things, its label or labeling fails to bear certain required 
information concerning the device, is false or misleading in any 
particular way, or fails to contain adequate directions for use.
    Reporting Burden
    Sections 800.10(a)(3) and 800.12(c) require that the label for 
contact lens cleaning solutions bear a prominent statement alerting 
consumers of the tamper-resistant feature. Further, Sec.  800.12 
requires that packaged contact lens cleaning solutions contain a 
tamper-resistant feature, to prevent malicious adulteration.
    Section 800.10(b)(2) requires that the labeling for liquid 
ophthalmic preparations packed in multiple-dose containers provide 
information on the duration of use and the necessary warning 
information to afford adequate protection from contamination during 
use.
    Section 801.1 requires that the label for a device in package form, 
contain the name and place of business of the manufacturer, packer, or 
distributor.
    Section 801.5 requires that labeling for a device include 
information on intended use as defined under Sec.  801.4 and provide 
adequate directions to assure safe use by the lay consumers.
    Section 801.61 requires that the principal display panel of an 
over-the-counter (OTC) device in package form must bear a statement of 
the identity of the device. The statement of identity of the device 
must include the common name of the device followed by an accurate 
statement of the principal intended actions of the device.
    Section 801.62 requires that the label for an OTC device in package 
form must bear a statement of declaration of the net quantity of 
contents. The label must express the net quantity in terms of weight, 
measure, numerical count, or a combination of numerical count and 
weight, measure, or size.
    Section 801.109 establishes labeling requirements for prescription 
devices, in which the label for the device must describe the 
application or use of the device, and contain a cautionary statement 
restricting the device for sale by, or on the order of an appropriate 
professional.
    For prescription by a licensed practitioner, Sec.  801.110 
establishes labeling requirements for a prescription device delivered 
to the ultimate purchaser or user. The device must be accompanied by 
labeling bearing the name and address of the licensed practitioner, 
directions for use, and cautionary statements if any, provided by the 
order.
    Section 801.150(e) requires a written agreement between firms 
involved when a non-sterile device is assembled or packaged with 
labeling that identifies the final finished device as sterile, for 
which the device is ultimately introduced into interstate commerce to 
an establishment or contract manufacturer to be sterilized. When a 
written agreement complies with the requirements under Sec.  
801.150(e), FDA takes no regulatory action against the device as being 
misbranded or adulterated. In addition, Sec.  801.150(e) requires that 
each pallet, carton, or other designated unit, be conspicuously marked 
to show its non-sterile nature when introduced into interstate 
commerce, and while being held prior to sterilization.
    Section 801.405(b)(1) provides for labeling requirements for 
articles, including repair kits, re-liners, pads, and cushions, 
intended for use in temporary repairs and refitting of dentures for lay 
persons. Section 801.405(b)(1) also requires that the labeling contain 
the word ``emergency'' preceding and modifying each indication-for-use 
statement for denture repair kits and the word ``temporary'' preceding 
and modifying each indication-for-use statement for re-liners, pads, 
and cushions.
    Section 801.405(c) provides for labeling requirements that contain 
essentially the same information described under Sec.  801.405(b)(1). 
The information is intended to enable a lay person to understand the 
limitations of using OTC denture repair kits, and denture re-liners, 
pads, and cushions.
    Section 801.420(c)(1) requires that manufacturers or distributors 
of hearing aids develop a user instructional brochure to be provided by 
the dispenser of the hearing aid to prospective users. The brochure 
must contain detailed information on the use and maintenance of the 
hearing aid.
    Section 801.420(c)(4) establishes requirements that the user 
instructional brochure or separate labeling, provide for technical data 
elements useful for selecting, fitting, and checking the performance of 
a hearing aid. In addition, Sec.  801.420(c)(4) provides for testing 
requirements to determine that the required data elements must be 
conducted in accordance with the American National Standards 
Institute's (ANSI) ``Specification of Hearing Aid Characteristics,'' 
ANSI S3.22-1996 (ASA 70-1996); (Revision of ANSI S3.22-1987), which is 
incorporated by reference in accordance with 5 U.S.C. 552(a) and 1 CFR 
part 51.
    Section 801.421(b) establishes requirement for the hearing aid 
dispenser to provide prospective users with a copy of the user 
instructional brochure along with an opportunity to review comments, 
either orally or by the predominant method of communication used during 
the sale.
    Section 801.421(c) establishes requirements for the hearing aid 
dispenser to provide a copy of the user instructional brochure to the 
prospective purchaser of any hearing aid upon request or, if the 
brochure is unavailable, provide the name and address of the 
manufacturer or distributor from which it may be obtained.
    Section 801.430(d) establishes labeling requirements for menstrual 
tampons to provide information on signs, risk factors, and ways to 
reduce the risk of Toxic Shock Syndrome (TSS).
    Section 801.430(e)(2) requires menstrual tampon package labels to 
provide information on the absorbency term based on testing required 
under Sec.  801.430(f) and an explanation of selecting absorbencies 
that reduce the risk of contracting TSS.
    Section 801.430(f) establishes requirements that manufacturers of 
menstrual tampons devise and follow an ongoing sampling plan for 
measuring the absorbency of menstrual tampons. Further, manufacturers 
must use the method and testing parameters described under this 
section.
    Section 801.435(b), (c), and (h) establishes requirements for 
condom labeling to bear an expiration date that

[[Page 21961]]

is supported by testing that demonstrates the integrity of three random 
lots of the product.
    Section 809.10(a) and (b) establishes requirements that a label for 
an in vitro diagnostic device and the accompanying labeling (package 
insert), must contain information identifying its intended use, 
instructions for use and lot or control number, and source.
    Section 809.10(d)(1) provides that the labeling requirements for 
general purpose laboratory reagents may be exempt from the requirements 
of Sec.  809.10(a) and (b), if the labeling contains information 
identifying its intended use, instructions for use, lot or control 
number, and source.
    Section 809.10(e) provides that the labeling for ``Analytic 
Specific Reagents'' (ASRs) must provide information identifying the 
quantity or proportion or each reagent ingredient, instructions for 
use, lot or control number, and source.
    Section 809.10(f) provides that, the labeling for OTC test sample 
collection systems for drugs of abuse must include information on the 
intended use, specimen collection instructions, identification system, 
and information about use of the test results. In addition, Sec.  
809.10(f) requires that this information be in a language appropriate 
for the intended users.
    Section 809.30(d) requires that advertising and promotional 
materials for ASRs include the identity and purity of the ASR and the 
identity of the analyte.
    Recordkeeping Burden
    Section 801.150(a)(2) establishes recordkeeping requirements for 
re-processors, re-labelers, or re-packagers to retain a copy of the 
agreement containing the specifications for the processing, labeling, 
or repacking of the device for 2 years after the shipment or delivery 
of the device. Section 801.150(a)(2) also requires that the subject 
respondents make copies of this agreement available for inspection at 
any reasonable hour to any officer or employee of the Department of 
Health and Human Services (DHHS), upon their request.
    Section 801.421(d) establishes requirements for hearing aid 
dispensers to retain copies of all physician statements or any waivers 
of medical evaluation for 3 years after dispensing the hearing aid.
    Section 801.410(e) requires copies of invoices, shipping documents, 
and records of sale or distribution of all impact resistant lenses, 
including finished eyeglasses and sunglasses, be maintained for 3 years 
by the retailer and made available upon request by any officer or 
employee of FDA or by any other officer or employee acting on behalf of 
the Secretary of Health and Human Services.
    Section 801.410(f) requires that the results of impact tests and 
description of the test method and apparatus be retained for a period 
of 3 years.
    Section 801.421(d) requires hearing aid dispensers to retain a copy 
of any written statement from a physician required under Sec.  
801.421(a)(1), or any written statement waiving medical evaluation 
required under Sec.  801.421(a)(2)(iii) for 3 years after the 
dispensing the hearing aid.
    Section 801.435(g) requires latex condom manufacturers to document 
and provide, upon request, an appropriate justification for the 
application of the testing data from one product on any variation of 
that product to support expiration dating in the user labeling.
    FDA estimates the burden of this collection of information as 
follows:

                                                     Table 1.--Estimated Annual Reporting Burden\1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                 No. of        Annual Frequency     Total Annual        Hours per
                      21 CFR Section                          Respondents       per  Response        Responses           Response         Total Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
800.10(a)(3) and 800.12(c)                                                 4                 10                 40                  1                 40
--------------------------------------------------------------------------------------------------------------------------------------------------------
800.10(b)(2)                                                               4                 10                 40                 40              1,600
--------------------------------------------------------------------------------------------------------------------------------------------------------
801.1                                                                 30,000                3.5            105,000                0.1             10,500
--------------------------------------------------------------------------------------------------------------------------------------------------------
801.5                                                                  5,000                3.5             17,500              22.35            391,125
--------------------------------------------------------------------------------------------------------------------------------------------------------
801.61                                                                 5,000                3.5             17,500                  1             17,500
--------------------------------------------------------------------------------------------------------------------------------------------------------
801.62                                                                 1,000                  5              5,000                  1              5,000
--------------------------------------------------------------------------------------------------------------------------------------------------------
801.109                                                               18,000                3.5             63,000              17.77          1,119,510
--------------------------------------------------------------------------------------------------------------------------------------------------------
801.110                                                               10,000                 50            500,000               0.25            125,000
--------------------------------------------------------------------------------------------------------------------------------------------------------
801.150(e)                                                                 2                  1                  2               0.50                  1
--------------------------------------------------------------------------------------------------------------------------------------------------------
801.405(b)(1)                                                             40                  1                 40                  4                160
--------------------------------------------------------------------------------------------------------------------------------------------------------
801.405(c)                                                                40                  1                 40                  4                160
--------------------------------------------------------------------------------------------------------------------------------------------------------
801.420(c)(1)                                                            275                  5              1,375                 40             55,000
--------------------------------------------------------------------------------------------------------------------------------------------------------
801.420(c)(4)                                                            275                  5              1,375                 80            110,000
--------------------------------------------------------------------------------------------------------------------------------------------------------
801.421(b)                                                            10,000                160          1,600,000               0.30            480,000
--------------------------------------------------------------------------------------------------------------------------------------------------------
801.421(c)                                                            10,000                  5             50,000               0.17              8,500
--------------------------------------------------------------------------------------------------------------------------------------------------------
801.430(d)                                                                 8                  5                 40                  2                 80
--------------------------------------------------------------------------------------------------------------------------------------------------------
801.430(e)(2)                                                              8                  5                 40                  2                 80
--------------------------------------------------------------------------------------------------------------------------------------------------------

[[Page 21962]]

 
801.430(f)                                                                 8                  5                 40                 80              3,200
--------------------------------------------------------------------------------------------------------------------------------------------------------
801.435(b), (c), and (h)                                                 135                  1                135                 96             12,960
--------------------------------------------------------------------------------------------------------------------------------------------------------
809.10(a) and (b)                                                      1,700                  6             10,200                 80            816,000
--------------------------------------------------------------------------------------------------------------------------------------------------------
809.10(d)(1)                                                             300                  2                600                 40             24,000
--------------------------------------------------------------------------------------------------------------------------------------------------------
809.10(e)                                                                300                 25              7,500                  1              7,500
--------------------------------------------------------------------------------------------------------------------------------------------------------
809.10(f)                                                                 20                  1                 20                100              2,000
--------------------------------------------------------------------------------------------------------------------------------------------------------
809.30(d)                                                                300                 25              7,500                  1              7,500
--------------------------------------------------------------------------------------------------------------------------------------------------------
Total                                                                                                                                          3,197,416
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.


                                                   Table 2.--Estimated Annual Recordkeeping Burden\1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                               Annual Frequency
                      21 CFR Section                             No. of              per            Total Annual    Hours per  Record     Total Hours
                                                             Recordkeepers      Recordkeeping         Records
--------------------------------------------------------------------------------------------------------------------------------------------------------
801.150(a)(2)                                                             57                  1                 57               0.50                 28
--------------------------------------------------------------------------------------------------------------------------------------------------------
801.410(e)                                                                30            769,000         23,070,000               0.25          5,767,500
--------------------------------------------------------------------------------------------------------------------------------------------------------
801.410(f)                                                                30            769,000         23,070,000               0.25          5,767,500
--------------------------------------------------------------------------------------------------------------------------------------------------------
801.421(d)                                                            10,000                160          1,600,000               0.25            400,000
--------------------------------------------------------------------------------------------------------------------------------------------------------
Total Hours                                                                                                                                   11,935,028
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.

    This regulation also refers to previously approved collections of 
information found in FDA regulations. The collections of information 
under Sec. Sec.  800.12(d) and 801.437(i) have been approved under OMB 
control number 0910-0183; the collections of information under Sec.  
800.12(e) have been approved under OMB control number 0910-0231; and 
the collections of information under Sec.  801.435(g) have been 
approved under OMB control number 0910-0073.
    Further, FDA concludes that labeling statements under Sec. Sec.  
801.63, 801.405(b)(2) and (b)(3), 801.420(c)(2) and (c)(3), 801.430(c) 
and (e)(1), 801.433, 801.437(d) through (g), 809.30(d)(2) and (d)(3), 
and 809.30(e) do not constitute a ``collection of information'' under 
the PRA. Rather, these labeling statements are ``public disclosure'' of 
information originally supplied by the Federal Government to the 
recipient for the purpose of ``disclosure to the public'' (5 CFR 
1320.3(c)(2)).
    Reporting
    These estimates are based on FDA's registration and listing 
database for medical device establishments, agency communications with 
industry, and FDA's knowledge of and experience with device labeling.
    Recordkeeping
    These estimates are based on FDA's registration and listing 
database for medical device establishments, agency communications with 
industry, and FDA's knowledge of and experience with device labeling. 
In addition, the Vision Council of America provided the growth rate 
used to estimate the burden under Sec.  801.410(e) through (f).
    This regulation also refers to previously approved collections of 
information found in FDA regulations. The collections of information 
under Sec. Sec.  800.12(d) and 801.437(i) have been approved under OMB 
control number 0910-0183; and the collections of information under 
Sec.  800.12(e) have been approved under OMB control number 0910-0231.
    The information collection requirements under Sec. Sec.  801.22, 
801.63, 801.405(b)(2) and (b)(3), 801.420(c)(2) and (c)(3), 801.430(c) 
and (e)(1), 801.433, 801.437(d) through (g), 809.30(d)(2) and (d)(3), 
and 809.30(e) are not considered information collection because the 
public information is originally supplied by the Federal Government to 
the recipient for the purpose of disclosure to the public (5 CFR 
1320.3(c)(2)).
    We have not estimated a burden for information that is disclosed to 
third parties, because it is a ``usual and customary'' part of a 
medical device manufacturer, distributor, or importer's normal business 
activities. Nor have we estimated a burden for time that is spent 
designing labels to improve the format or presentation.
    Please note that on January 15, 2008, the FDA Division of Dockets 
Management Web site transitioned to the Federal Dockets Management 
System (FDMS). FDMS is a Government-wide, electronic docket management 
system. Electronic comments or submissions will be accepted by FDA only 
through FDMS at http://www.regulations.gov.

    Dated: April 16, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and Planning.
[FR Doc. E8-8710 Filed 4-22-08; 8:45 am]
BILLING CODE 4160-01-S